Get your COVID-19 Vaccine. All Delawareans 12+ are now eligible.

Questions? Email us: Vaccine@delaware.gov

The general public will have an important role in COVID-19 prevention. While the majority of the general public will not be able to receive the COVID-19 vaccine until late spring or early summer, it is important that everyone follows guidelines until then such as practice hand hygiene, social distancing, and wearing face coverings. When the vaccine does become available, you should plan on getting two doses. Below are resources to assist you in your planning efforts.

 

Johnson & Johnson Materials

Moderna Call Center:

1-866-MODERNA (1-866-663-3762)

General Moderna Questions  Healthcare Provider Questions (clinical) Product Quality or Technical Questions Pregnancy Registry

Note: Call center volume, per Moderna has an approx. call volume of 200 calls/hour during peak operational hours of 8:00 a.m.- 8:00 p.m. EST

CDC & FDA Resources


Vaccine FAQs

A vaccine is a substance that teaches your body to recognize that a foreign invader such as a virus or bacteria has entered the body. Once the body recognizes the invader, the body’s immune system is activated, and fighter cells and proteins fight the virus or the bacteria. A vaccine is much like a decoy, it tricks the body into thinking it is the virus, but it does not actually cause the disease. It helps your body fend off the virus.

Currently, the vaccine is available to the following groups:

  • Seniors 65 and older should contact pharmacies for the vaccine or sign up at delaware.gov to request to be put on the state’s wait list for a vaccination appointment.
  • Frontline and essential workers will receive information about getting a vaccine from their employers. They should check with their employers first about whether they plan to partner with a pharmacy or hospital to provide vaccinations onsite. They may also receive invitations to state-run events through their employer.
  • Individuals 50 and older can sign up through pharmacies and can also sign up at delaware.gov to request to be put on the state’s wait list for a vaccine appointment.
  • Individuals 16-64 with high-risk underlying health conditions that could lead to severe COVID-19 complications should contact their primary care provider or hospital for a vaccination appointment. Their non-paid family caregivers are also eligible for vaccination. If your provider is not vaccinating patients, they will refer you to a hospital system.  Look here for a list of qualifying conditions: https://coronavirus.delaware.gov/vaccine/where-can-i-get-my-vaccine/medical-providers/.

The Delaware vaccine effort is led by the Division of Public Health in partnership with the state’s COVID Vaccine Task Force. The State’s Ethics Committee also provided recommendations on priority groups that should receive the vaccines first. DPH staff met internally to develop a response to the CDC’s request for information. The response, called The Playbook, can be found at https://coronavirus.delaware.gov/vaccine/.

The vaccine will be given to the American people at no cost. However, vaccination providers may be able to charge an office visit fee and will be able to charge an administration fee for giving the vaccine. Vaccine providers can be reimbursed for this fee.

The vaccine is available from Primary Care Providers, pharmacies, Federally Qualified Health Centers, and from events coordinated by Public Health or its partners Curative, or Vault Health, and community-based organizations that are either partnering with the state or hospital systems. The best source of information about availability is https://coronavirus.delaware.gov/vaccine/where-can-i-get-my-vaccine/.

The Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine, both FDA-approved for Emergency Use, require two shots. Individuals need to receive the same brand of vaccine for their second dose to be effective. The second shot of the Pfizer-BioNTech vaccine must be given three weeks after the initial dose. Moderna requires its second shot to be given one month after the original dose. The second dose should be received as close as possible to the 21 day/28 day time, but does not have to be on the precise day and can be administered later without repeating the series. The Johnson & Johnson vaccine only requires one dose. People are encouraged to take whatever vaccine is being offered to them rather than wait for a specific brand.

All three vaccines, Pfizer, Moderna and Johnson&Johnson are 100% effective at preventing COVID-19 related death and hospitalization. Pfizer-BioNTech and Moderna are 95% effective against all forms of COVID infections, and the J&J/Janssen vaccine is 74% effective. In comparison, the annual flu vaccine is typically between 40% and 60% effective in preventing influenza. It is unknown how long the COVID vaccine’s effectiveness will last, so an annual vaccine (much like the flu) may be required.

Yes. According to the CDC, experts are still learning how a vaccine will provide protection under real-life conditions. For that reason, everyone will need to continue following CDC guidelines such as wearing a mask over your mouth and nose, frequent hand washing and staying fix feet away from others. According to the CDC’s updated guidelines, there are some exceptions. People who are fully vaccinated can gather inside with others who have also been fully vaccinated without a mask. Fully vaccinated individuals can also gather indoors with unvaccinated individuals from one other house without masks only if those individuals are not at a risk for severe COVID-19 illness. It’s important to note that these guidelines only apply to household gatherings indoors.  Masks are still required in public places, outside, and in the workplace.

There is a five-step process for vaccine approval in the U.S.: 1) Clinical trials 2) FDA Review and approval or Emergency Use Authorization 3) Manufacturing 4) Distribution and 5) Post vaccine safety monitoring.  The U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research is responsible for regulating vaccines in the United States. A company that wants to bring a new vaccine to market first needs to file an application with the FDA, describing its vaccine, its method for manufacturing and its quality control tests. Vaccine approvals follow the same process that other drugs follow.

Yes. Recognizing the importance of testing within minority populations, vaccine developers worked with community engagement partners to enroll a diverse pool of volunteers in the clinical trials. Thirty-seven percent of volunteers from one manufacturer’s clinical trials alone were from racial and ethnic minority groups. Johnson & Johnson’s study also included volunteers from diverse racial and ethnic minority groups.

Here are the racial and ethnic breakdowns of participants in each vaccines’ clinical studies:

Pfizer BioNTech:

  • Diverse subjects in study: 42%
  • Asian: 5%
  • Black: 10%
  • Hispanic: 26%
  • Native American: 1%

DPH, with recommendations from the Delaware Public Health Medical Ethics Advisory Group (Ethics Group) review the CDC list of prioritized population groups and determine allocation and distribution of vaccine(s). The Ethics Group recommendations are made based on which groups are most at risk due to how the virus is transmitted (close contact, indoor facilities), the severity rate of the virus in the community, and based on the prioritized population groups.  Additionally, both Delaware’s COVID Vaccine Task Force and the Communications subcommittee, include representation from organizations representing communities of color and incorporate their feedback into planning.

In February, DPH issued an order, formalizing requirements for second doses of the vaccine. In that order, the Division included that heath care providers are prohibited from denying administration of the COVID-19 vaccine for reasons of race, color, gender, ethnicity, disability, national origin or any other protected status. DPH also emphasized the importance of providers recording race and ethnicity when reporting vaccinations in order to evaluate efforts to vaccinate underserved populations. The state has established multiple pathways to ensure that underserved communities also have access to the vaccine.  These pathways include allocating vaccine to pharmacies and medical providers located in traditionally underserved areas, Federally Qualified Health Centers whose primary mission is to serve vulnerable populations, and partnering with community-based organizations within vulnerable communities.

The side effects have been minimal for both vaccines and generally go away within 24 hours. To report side effects, call 1-800-822-7967 or vaers.hhs.gov/reportevent

  • Pfizer-BioNTech Side Effects: Injection site pain, tiredness, headache, muscle pain, chills, joint pain, fever, injection site swelling, injection site redness, nausea, feeling unwell and swollen lymph nodes.
  • Moderna COVID-19 Side Effects: pain and tenderness at the injection site, swelling of the lymph nodes in the arm of the injection site, fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting and fever.
  • Johnson & Johnson Side Effects: pain, swelling and redness at the injection site, tiredness, headache, muscle pain, chills, fever, nausea and tiredness within a day or two of receiving the vaccine.
  • Rare Severe Allergic Reactions: In some rare cases, severe allergic reactions have occurred within minutes to an hour of receiving both the Pfizer BioNTech and the Moderna vaccines. Signs of a severe allergic reaction include trouble breathing, swelling of face and throat, rapid heartbeat, dizziness and a rash that covers the whole body. If you experience any of these symptoms call 9-1-1 immediately or go to the nearest hospital.

The vaccine was developed in a much shorter period of time, due to the obvious need to address the public health threat the pandemic posed to the nation. A shorter development and review time does not mean the vaccine is unsafe.

The shorter development time is the result of technology advances to map the virus’s DNA and using vaccine platforms developed for other diseases that were in place to both develop and test the vaccine. The Coronavirus that causes COVID-19 is part of a broader family of coronaviruses. It is related to the severe respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researches have been engaged in searching for vaccines for those closely related viruses for several years, so they are not starting from scratch, according to the Mayo Clinic.

The clinical trial process was accelerated by enrolling more people in trials to enhance rapid data collection and earlier analysis of safety data for demographically diverse populations.  This also sped up the FDA review process as they have been monitoring the data all along.  Delivery/distribution time was shortened by allowing manufacturing to occur at the same time as instead of after, vaccine approval.

Experts and scientists from the Food and Drug Administration and the Advisory Committee on Immunization Practices review the vaccine development data. Extensive post-monitoring efforts will be implemented to safeguard those immunized.

Additional actions that U.S. government has taken to expedite the development and manufacturing of the vaccine include:

  • Larger studies: The federal government is allowing manufacturers to conduct larger studies that allow it to reach objectives sooner than it would conducting smaller studies.
  • Financial Investment: The U.S. government has made a financial commitment, making it possible for companies to manufacture large amounts of a vaccine without taking on all of the financial risks.
  • U.S. Food & Drug Administration: The FDA has expedited clinical trials and is providing timely advice and interactions with vaccine developers.

 

Those actions have been taken under the federal government’s Operation Warp Speed which is the coordinated federal effort to produce a safe and effective vaccine against COVID-19.

No. Information about the studies and the candidates can be found on the following website https://coronaviruspreventionnetwork.org/understanding-clinical-studies/ or by visiting the manufactures websites.

  • Johnson and Johnson: Genetically engineered. Does not contain the virus.
  • Moderna: Genetically engineered. Does not contain the virus.
  • AstraZeneca: It contains a weakened version of the virus.
  • Pfizer: It contains a small part of the genetic code but does not contain the live virus.

 

It is too soon to tell. In general, vaccines prevent or reduce the seriousness of various diseases.  Vaccines have been used successfully for decades to control and contain diseases such as polio, chicken pox, measles, mumps and the seasonal flu, but did not eliminate them altogether. However, a vaccine, did eliminate smallpox.

It is still unknown at this time, how long that would take, but the more people who choose to get the vaccine, the greater chance of reaching herd immunity there will be.

The Division of Public Health encourages but does not plan to require that everyone get the vaccine.

No, they cannot give someone COVID-19. mRNA vaccines do not use the live virus that causes COVID-19.

mRNA vaccines contain material from the virus that causes COVID-19 that gives our cells instructions for how to make a harmless protein that is unique to the virus. After our cells make copies of the protein, they destroy the genetic material from the vaccine.

No. They do not affect or interact with our DNA in any way.

An appointment request system has been created with the following: (1) An individual will request an appointment at vaccinerequest.delaware.gov which will put them on a waiting list and (2) when appointments become available, invitation emails will be sent to individuals to schedule an appointment online for an upcoming event. Seniors with computer access are advised to request an appointment through this online system, which will be available in English, Spanish and Haitian Creole.  It is highly recommended the online system be used, but those without computer access may call the COVID-19 Vaccine Call Center at 1-833-643-1715 and a call center operator can assist you in making the initial request.  Multiple requests will not increase the chance of receiving an invitation for an appointment.

You should not get the COVID-19 vaccine:

  • If you have had a severe allergic reaction (anaphylaxis) or an immediate allergic reaction—even if it was not severe—to any ingredient in an mRNA COVID-19 vaccine (such as polyethylene glycol), you should not get an mRNA COVID-19 vaccine.*
  • If you have had a severe allergic reaction (anaphylaxis) or an immediate allergic reaction—even if it was not severe—after getting the first dose of the vaccine, you should not get a second dose of either of the mRNA COVID-19 vaccines.*
  • An allergic reaction is considered severe when a person needs to be treated with epinephrine or EpiPen© or if they must go to the hospital. Learn about common side effects of COVID-19 vaccines and when to call a doctor.
  • An immediate allergic reaction means a reaction within 4 hours of getting vaccinated, including symptoms such as hives, swelling, or wheezing (respiratory distress).

You should not get the COVID-19 vaccine if you:

• had a severe allergic reaction after a previous dose of the vaccine
• had a severe allergic reaction to any ingredient of the vaccine.

The following age groups are authorized to receive vaccination:

  • Pfizer-BioNTech: ages ≥16 years
  • Moderna: ages ≥18 years
  • Janssen: ages ≥18 years

Children and adolescents outside these authorized age groups should not receive COVID-19 vaccination at this time.

It is not recommended you take over-the-counter medicine, such as ibuprofen, aspirin, or acetaminophen, before vaccination for the purpose of trying to prevent vaccine-related side effects. It is not known how these medications may affect how well the vaccine works. However, if you take these medications regularly for other reasons, you should keep taking them before you get vaccinated. It is also not recommended to take antihistamines before getting a COVID-19 vaccine to try to prevent allergic reactions.

The Division of Public Health recommends that you take any of the vaccines that are available once you are eligible and receive an invitation for an appointment. However, we understand that you may want to compare vaccines. You can see a comparison chart here.

Vaccine provided at each vaccination site is dependent upon supply received. Choice of vaccine is not available. When you receive the vaccine, you will receive a card that states which vaccine was provided, including company name, lot number, date received and location.

 

Even if you have already recovered from COVID-19, it is possible—although rare—that you could be infected with the virus that causes COVID-19 again. You should wait at least 10 days after your isolation period ends to get the vaccine.

If you were treated for COVID-19 with monoclonal antibodies or convalescent plasma, you should wait 90 days before getting a COVID-19 vaccine. Talk to your doctor if you are unsure what treatments you received or if you have more questions about getting a COVID-19 vaccine.

Experts are still learning more about how long vaccines protect against COVID-19 in real-world conditions. CDC will keep the public informed as new evidence becomes available.

Persons 16+ with an intellectual or developmental disability, or a physical one caused by a medical condition (such as ALS or cerebral palsy) should contact their physician or a hospital system (if you receive services there).  If your physician is not vaccinating, they will refer your name to a hospital system who will reach out to either schedule you or advise you how to get on their waitlist. Going through a medical provider or hospital system is the best way for those with underlying health conditions to be vaccinated as they are very familiar with your conditions.  Those with other physical disabilities who are 50+ can either check with a pharmacy to identify their accommodations, or if signed up for the state’s waitlist, can contact the Vaccine Call center to inquire about accommodations that are available when you receive an invitation to schedule an appointment.  The vaccine call center can be reached at 1-833-643-1715 or vaccine@delaware.gov.

DPH coordinated vaccination sites (drive thru or indoor sites) that are open to the public meet ADA requirements. Accommodations will be available at the site to assist with the vaccination process, including large print materials. Contact the vaccine call center at 1-833-643-1715 or email Vaccine@delaware.gov  to request accommodations at a state-coordinated large scale vaccination site.

Contact the DPH Vaccine Call Center at 1-833-643-1715 or email Vaccine@delaware.gov  with questions regarding accommodations. Staff may need to get back to you with more information, or may need to connect you to the DHSS Aging and Disabilities Resource Center.

The Division of Public Health is currently investigating options for assisting members of the general public with their transportation needs. Eligible Delaware Medicaid clients in need of non-emergency transportation should contact Modivcare at 1-866-412-3778. Homebound individuals or DHSS clients should contact the Vaccine Call Center at 1-833-643-1715, and they will take your information to provide to the Aging and Disabilities Resource Center.

If you are pregnant, you may choose to be vaccinated when it’s available to you. There is currently no evidence that antibodies formed from COVID-19 vaccination cause any problem with pregnancy, including the development of the placenta.

People who are trying to become pregnant now or who plan to try in the future may receive the COVID-19 vaccine when it becomes available to them. There is no evidence that fertility problems are a side effect of any vaccine, including COVID-19 vaccines. There is no routine recommendation for taking a pregnancy test before you get a COVID-19 vaccine.

If you have questions about getting vaccinated, talking with a health care provider may might help you make an informed decision. Learn more at vaccination considerations for people who are pregnant or breastfeeding from the CDC, or view Delaware’s Fact Sheet on Pregnancy and Fertility here.

All three vaccines have slight differences, but all have been proven 100% effective in preventing hospitalization and death from COVID-19. The Division of Public Health recommends that you take whichever vaccine becomes available to you rather than waiting for a specific brand, however, we understand that you may want to compare the vaccines yourself. You can see a vaccine comparison chart here.

The CDC is advising people who are due for a mammogram to speak with their medical provider on how long they should wait until after they receive their vaccine to get their mammogram. The vaccine can cause lymph nodes under the arms to swell, which can cause a false reading on a mammogram. According to the CDC, some experts recommend getting a mammogram first before receiving the vaccine or waiting four to six weeks after being vaccinated to get a mammogram. For more details on this and how the vaccine affects other medical procedures visit https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/other-procedures.html#.

  • People with COVID-19 who have symptoms should wait to be vaccinated until they have recovered from their illness and have met the criteria for discontinuing isolation; those without symptoms should also wait until they meet the criteria before getting vaccinated. You should wait at least 10 days after your isolation period ends to get the vaccine.

 

Preguntas frecuentes sobre la vacuna contra el COVID-19

Una vacuna es una sustancia que le enseña al cuerpo a detectar el ingreso de un invasor extraño, como un virus o una bacteria. Una vez que el organismo reconoce al invasor, se activa el sistema inmunitario, y las células y las proteínas combativas atacan al virus o la bacteria. Una vacuna es una especie de señuelo, que le hace creer al cuerpo que es el virus, pero en realidad no causa la enfermedad. Ayuda al organismo a defenderse del virus.

Se espera que para principios de diciembre haya una cantidad limitada de vacunas destinada a los grupos de alto riesgo, incluidos los trabajadores de la salud, personal de servicios de emergencia y empleados de centros de atención a largo plazo. Es muy probable que la segunda ronda de vacunas sea para los proveedores de atención primaria, el personal de atención de urgencias, personas con enfermedades subyacentes y aquellas que vivan en ciertos entornos multitudinarios. Es posible que el público en general recién tenga acceso a la vacuna en la primavera de 2021. La vacuna solo se ha probado ampliamente en adultos, excepto mujeres embarazadas; por lo que es probable que al principio no se la recomienden a embarazadas o niños.

La División de Salud Pública (DPH), en colaboración con el Grupo de Trabajo de Vacunación contra el COVID del estado, lidera el trabajo de planificación de la vacuna en Delaware. Primero se reunió el personal de la DPH en forma interna para desarrollar una respuesta ante el pedido de información de los Centros para el Control y la Prevención de Enfermedades (CDC). La respuesta se compiló en una Guía que se puede consultar en https://coronavirus.delaware.gov/vaccine/.

Por su parte, el Grupo de Trabajo se ha reunido cada semana para garantizar que tanto los colaboradores como otras partes interesadas reciban la información más actual; se han reunido los subcomités que se crearon para diferentes funciones específicas; el Comité de Ética del Estado se reunió con el fin de brindar recomendaciones iniciales sobre los grupos prioritarios para recibir la vacuna; la DPH realizó un ejercicio de simulación para identificar lagunas en la planificación; se contrataron proveedores médicos para administrar la vacuna una vez que esté ampliamente disponible; y se capacitó al personal del Programa de Inmunizaciones en el uso del sistema nacional de seguimiento de vacunas (Tiberius) para prever la asignación de vacunas, hacer un seguimiento de los pedidos de vacunas, llevar un registro de la asignación de recursos, etc.

La vacuna se administrará al pueblo estadounidense de manera gratuita. No obstante, es posible que a los proveedores del servicio de vacunación se les permita cobrar honorarios de consulta y un cargo de administración por la aplicación de la vacuna. Dichos proveedores pueden obtener un reembolso de este costo.

En un principio, cuando la vacuna esté disponible solo para ciertos grupos específicos, los sistemas hospitalarios y los organismos de servicios médicos de emergencia vacunarán al personal. Cuando el acceso a la vacuna se haga extensivo al público, podrán administrar la vacuna los proveedores de atención primaria, las farmacias, los Centros de Salud Aprobados por el Gobierno Federal (FQHC) y los organismos de salud pública. Un localizador basado en la Web llamado Vaccine Finder (https://vaccinefinder.org/find-vaccine) incluirá los lugares que la provean tan pronto como estén disponibles.

Actualmente, tres de las cuatro vacunas contra el COVID-19 que se encuentran en la fase final de investigación en los Estados Unidos requieren dos inyecciones para ser eficaces. La cuarta requiere una sola dosis.

Según se informó, las dos candidatas principales tienen una eficacia (éxito) del 90 %, con unos pocos efectos secundarios leves. En comparación, la vacuna antigripal anual suele tener una eficacia de entre un 40 % y un 60 %. Se desconoce la duración de los efectos de la vacuna contra el COVID, por lo que es posible que se requiera una dosis anual, como es el caso de la vacuna antigripal.

Sí. Según los CDC, los especialistas siguen aprendiendo sobre la protección de la vacuna en condiciones reales. Por ese motivo, es necesario seguir respetando los lineamientos de los CDC, como usar una mascarilla que cubra la boca y la nariz, lavarse las manos con frecuencia y mantener una distancia mínima de seis pies de los demás.

El proceso de aprobación de vacunas en los EE. UU. consta de cinco pasos: 1) ensayos clínicos; 2) revisión y aprobación, o autorización de uso de emergencia, por parte de la FDA; 3) fabricación; 4) distribución, y 5) control posterior de la seguridad de la vacuna. El Centro para la Evaluación e Investigación de los Productos Biológicos de la FDA es responsable de la regulación de las vacunas en los Estados Unidos. Cuando una compañía quiere introducir una nueva vacuna al mercado, primero debe presentar una solicitud a la FDA que incluye una descripción de la vacuna, el método de fabricación y las pruebas de control de calidad. El proceso de aprobación para las vacunas es el mismo que para el resto de los fármacos.

Por lo general, los ensayos clínicos de las vacunas constan de tres fases.

  • Primera fase: En esta fase se prueba la seguridad de la vacuna. Se la administra a una pequeña cantidad de personas para identificar los efectos secundarios y ver si el cuerpo puede tolerarla. Algunas personas del grupo de estudio reciben un placebo, que no tiene ingredientes activos.
  • Segunda fase: En esta fase, se administra la vacuna a más personas. El objetivo de esta fase es recopilar más información sobre los efectos secundarios comunes a corto plazo y la relación entre el tamaño de la dosis y la reacción del sistema inmunitario.
  • Fase 3: La vacuna se administra a una gran cantidad de personas, y se realizan pruebas minuciosas. En esta fase se observa si la vacuna realmente funciona y previene nuevas infecciones, o si ayuda a las personas infectadas a controlar la infección y evitar síntomas graves. De manera aleatoria, se asignan más personas para recibir la vacuna o el placebo.

En cualquier etapa de un ensayo clínico, si los datos indican problemas de seguridad o eficacia, la FDA puede detener los ensayos clínicos o solicitar más información y estudios. Si la compañía pasa las tres fases de manera satisfactoria, puede solicitar una licencia para productos biológicos, que se somete a la revisión de un equipo integrado por funcionarios médicos, microbiólogos, especialistas en bioestadística y otros profesionales. Después de la revisión, la compañía farmacéutica y la FDA presentan sus conclusiones ante el Comité Asesor de Vacunas y Productos Biológicos Relacionados de la FDA.

El desarrollador también tiene la opción de solicitar una autorización de uso de emergencia (EUA). El proceso de EUA fue establecido por el Congreso después de los ataques del 9/11 a fin de permitir a los desarrolladores acelerar la disponibilidad de un producto para el público en condiciones de emergencia, cuando los beneficios conocidos superan los riesgos potenciales.

Conscientes de la importancia de las pruebas en las poblaciones minoritarias, los desarrolladores de las vacunas trabajaron junto a colaboradores especializados en campañas de participación comunitaria para inscribir a un grupo diverso de voluntarios en los ensayos clínicos. El 37 % de los voluntarios del ensayo clínico de uno de los fabricantes pertenecían a grupos de minorías étnicas y raciales. Se dará a conocer más información a medida que esté disponible.

Teniendo en cuenta las recomendaciones del Grupo Asesor de Salud Pública y Ética Médica de Delaware (en adelante, el Grupo de Ética), la DPH revisará la lista de los CDC de poblaciones prioritarias y determinará la asignación y distribución de las vacunas. Las recomendaciones del Grupo de Ética se basarán en los grupos de mayor riesgo debido a la forma de contagio del virus (contacto estrecho, espacios cerrados), el índice de gravedad del virus en la comunidad, y las poblaciones prioritarias. Los miembros de las comunidades afroamericanas trabajan en muchas de las industrias identificadas para la vacunación de nivel 1 y nivel 2. Asimismo, tanto el Grupo de Trabajo de Vacunación contra el COVID de Delaware como el subcomité de comunicaciones incluyen integrantes de organizaciones que representan a las comunidades afroamericanas e incorporan sus observaciones en la planificación.

Los dos desarrolladores con más probabilidades de producir primero una vacuna contra el COVID-19 indicaron que existen muy pocos efectos secundarios, y que ninguno de ellos es grave. Los más comunes son dolor en el lugar de la inyección, fatiga, dolores musculares y dolor de cabeza, y suelen durar poco tiempo. La Administración de Medicamentos y Alimentos (FDA) y los Centros para el Control y la Prevención de Enfermedades (CDC) continuarán supervisando la seguridad de las vacunas contra el COVID-19 para garantizar que se identifiquen hasta los efectos secundarios menos frecuentes.

La vacuna se desarrolló en un período mucho más corto debido a la obvia necesidad de abordar la amenaza a la salud pública que enfrenta la nación a raíz de la pandemia. Un tiempo de desarrollo y revisión más breve no implica que la vacuna no sea segura.

La reducción de los tiempos de desarrollo es el resultado de los avances tecnológicos para mapear el ADN del virus y del uso de plataformas de vacunas creadas para otras enfermedades que estaban en funcionamiento para desarrollar y probar la vacuna. El coronavirus que causa COVID-19 es parte de una familia más grande de coronavirus. Está relacionado con el síndrome respiratorio agudo grave (SARS) y el síndrome respiratorio de Oriente Medio (MERS). Según la Clínica Mayo, los investigadores se han dedicado durante años a estudiar vacunas para estos virus relacionados, de modo que las investigaciones actuales no empezaron de cero.

El proceso de los ensayos clínicos se aceleró inscribiendo a más personas en los ensayos para mejorar la recopilación rápida de datos y el análisis más temprano de los datos de seguridad sobre poblaciones demográficamente diversas. Esto también aceleró el proceso de revisión de la FDA, ya que iba supervisando los datos en simultáneo. El tiempo de entrega/distribución se acortó al permitir que la fabricación tuviera lugar mientras se aprobaba la vacuna, y no después.

Especialistas y científicos de la FDA y el Comité Asesor sobre Prácticas de Vacunación (ACIP) revisaron los datos de desarrollo de la vacuna. Se llevará a cabo un exhaustivo trabajo de control posterior para proteger a quienes se hayan vacunado.

A continuación, se incluyen otras medidas que ha tomado el gobierno de EE. UU. para acelerar el desarrollo y la fabricación de la vacuna:

  • Estudios de mayor envergadura: El gobierno federal autorizó a los fabricantes a realizar estudios de mayor envergadura para alcanzar objetivos más rápido que si fueran de menor escala.
  • Inversión económica: El gobierno estadounidense asumió un compromiso financiero que permitió a las empresas fabricar grandes cantidades de vacuna sin absorber todos los riesgos financieros.
  • Administración de Medicamentos y Alimentos de los EE. UU.: La FDA aceleró los ensayos clínicos y ha asesorado e interactuado de manera oportuna con los desarrolladores.

Dichas acciones se llevaron a cabo de acuerdo con la iniciativa federal coordinada “Operación Velocidad de la Luz” (Operation Warp Speed), impulsada por el gobierno nacional para producir una vacuna segura y eficaz contra el COVID-19.

No. La información sobre los estudios y las vacunas candidatas puede consultarse en el sitio web https://coronaviruspreventionnetwork.org/understanding-clinical-studies/ o en los sitios web de los fabricantes.

  • Johnson and Johnson: Diseñada genéticamente. No contiene el virus.
  • Moderna: Diseñada genéticamente. No contiene el virus.
  • AstraZeneca: Contiene una versión atenuada del virus.
  • Pfizer: Contiene una pequeña porción del código genético, pero no contiene el virus activo.

Es demasiado pronto para saberlo. Por lo general, las vacunas previenen diversas enfermedades o reducen su gravedad. Durante décadas, las vacunas han controlado y contenido de manera exitosa enfermedades como la poliomielitis, la varicela, el sarampión, las paperas y la gripe estacional, pero no las eliminaron por completo. Sin embargo, una vacuna sí erradicó la viruela.

Aún no se sabe cuánto tardará, pero cuantas más personas elijan vacunarse, mayor será la probabilidad de alcanzar la inmunidad de rebaño.

Las vacunas ARNm contienen material del virus que causa COVID-19. Ese material les da instrucciones a nuestras células para que desarrollen una proteína inofensiva que es específica del virus. Después de que nuestras células hacen copias de la proteína, destruyen el material genético de la vacuna.

La División de Salud Pública recomienda que se vacune toda la población, pero no tiene intenciones de exigirlo.

Los dos desarrolladores con más probabilidades de producir primero una vacuna contra el COVID-19 indicaron que existen muy pocos efectos secundarios potenciales, y que ninguno de ellos es grave. Los más comunes son dolor en el lugar de la inyección, fatiga, dolores musculares y dolor de cabeza, y suelen desaparecer en el plazo de 24 horas. Dicho esto, ciertos organismos reaccionan diferente, y es posible que algunas personas tengan síntomas más fuertes que otras. La Administración de Medicamentos y Alimentos (FDA) y los Centros para el Control y la Prevención de Enfermedades (CDC) continuarán supervisando la seguridad de las vacunas contra el COVID-19 para garantizar que se identifiquen hasta los efectos secundarios menos frecuentes.


Report Vaccination Violations

Submit complaints about a vaccination provider by using this form, if you think they are violating any of these requirements.

Additionally, any health care provider who intentionally or willfully provides or distributes, or who supervises someone who intentionally or willfully provides or distributes the COVID-19 vaccine to any individual who is not authorized to receive such vaccine pursuant to the Vaccination Guidance is guilty of unprofessional conduct as defined in Title 24 and may be subject to licensure discipline. Send your complaints to Division of Professional Regulation about this conduct.

Get More COVID Data

For more data on Delaware COVID cases, testing and outcomes, including demographic breakdowns, go to My Healthy Community